Neos Therapeutics to Present at the Cowen & Co. Annual Health Care Conference
Source: Nasdaq GlobeNewswire / 06 Mar 2019 08:01:28 America/New_York
DALLAS and FORT WORTH, Texas, March 06, 2019 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release (XR) products using its proprietary modified-release drug delivery and orally disintegrating tablet (ODT) technology platforms, today announced that Jerry McLaughlin, Chief Executive Officer of Neos Therapeutics, will present a company overview at the upcoming Cowen & Co. 39th Annual Health Care Conference on Wednesday, March 13, 2019 at 11:20 a.m. ET in Boston, MA.
A live webcast of the presentation will be available on the Investor Relations page of the company’s website at http://investors.neostx.com/. Following the presentation, a replay of the webcast will be available on Neos’ website for 30 days.
About Neos Therapeutics
Neos Therapeutics, Inc. (NASDAQ: NEOS) is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING), Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING), and Adzenys-ER™ (amphetamine) extended-release oral suspension (see Full Prescribing Information, including Boxed WARNING), all for the treatment of ADHD, are three approved products using the Company’s extended-release technology platform. Additional information about Neos is available at www.neostx.com.
Richard I. Eisenstadt
Chief Financial Officer
Stern Investor Relations, Inc.